Skip to content
Laxxon Medical

For patients and pharma partners

Oral medicines designed around patients

Laxxon Medical is a drug development company. It develops oral medicines designed to make treatment simpler for patients: several active ingredients in one tablet, fewer doses a day and tablets instead of injections. For pharma partners, Laxxon turns established active ingredients into new products that can carry their own patent protection.

Focus program · LXM.2

An oral GLP-1 RA, enabled by SPID® technology

The challenge

Most GLP-1 RA medicines are peptides, and peptide medicines usually have to be injected. Peptides are large molecules that pass poorly through the gut wall and are broken down by enzymes and bacteria in the gastrointestinal tract. As a result, only a small fraction of an oral dose reaches the bloodstream (low oral bioavailability).

The approach

SPID® prints without heat, so heat-sensitive active ingredients such as peptides stay intact. SPID®-printed dosage forms are designed to protect the peptide from enzymes and bacteria on its way through the gastrointestinal tract and to release it where it can be absorbed, with the aim of improving oral bioavailability. For LXM.2, Laxxon is developing SPID®-printed oral GLP-1 RA microtablets.

The status

In preclinical development, with Phase 1 planned for 2027.

Sources: Drucker DJ, Advances in oral peptide therapeutics, Nature Reviews Drug Discovery 2020;19:277–289; company information and press release of October 21, 2026.

LXM.2 in the pipeline →

One platform, a pipeline of medicines

  1. Design

    SPID® prints tablets layer by layer, so release profile, dose and combinations of active ingredients can be designed into each tablet.

  2. Develop

    Laxxon uses SPID® to develop new oral dosage forms of newly developed molecules or established active ingredients for the FDA 505(b)(2) pathway.

  3. Protect

    Each new dosage form can carry its own patent protection. Including in-licensed rights, Laxxon's portfolio comprises more than 230 patents and patent applications, with terms potentially extending into 2046 (company figures, November 2026).

Explore the platform →

In-house pipeline

Laxxon develops its own Advanced Patented Generics: established active ingredients in new oral dosage forms.

Focus program

LXM.2

Obesity and metabolic disease (oral GLP-1 RA)

Phase 1 planned (2027)

SPID®-printed oral GLP-1 RA microtablets increased bioavailability by a factor of 10.1 in an animal study.Source: Press release, October 21, 2026; factor 10.1: company data, animal study

LXM.5

Parkinson's disease (levodopa/carbidopa)

Phase 1 in preparation

First dosing planned for early 2027

More than 380% higher bioavailability than Sinemet® in a published animal PK study. Designed to reduce intake to 2 to 3 tablets a day.Source: Pharmaceutics, 2025; tablets a day: company target

Partner program

LXM.8

Chronic weight management (enobosarm)

Phase 1 completed

Completed in August 2025

Formulation selected by the partner after a clinical PK studySource: Partner's press release, August 11, 2025

Six further programs in preclinical development

    Full pipeline →

    Partnering

    • Pipeline assets

      Licensing and co-development of Laxxon's own assets.

    • Co-development

      New SPID® dosage forms of a partner's active ingredient, developed jointly.

    • Lifecycle management

      New SPID® dosage forms of established products.

    How we partner →

    Manufacturing partner

    Adare Pharma Solutions

    Adare Pharma Solutions

    CDMO for clinical-scale cGMP manufacturing of Laxxon's programs, Pessano (Milan), Italy

    Meet us

    Jefferies Global Healthcare Conference

    November 16–19, 2026 · London

    J.P. Morgan Healthcare Conference

    January 11–14, 2027 · San Francisco

    Request a meeting →

    Company facts

    As of November 2026

    Company
    Laxxon Medical Corp., a privately held drug development company
    Founded
    2017
    Headquarters
    261 Madison Avenue, 9th Floor, New York, NY 10016, USA
    Research and development
    Laxxon Medical GmbH, Jena, Germany
    Intellectual property
    Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of 230 patents and patent applications with more than 5,500 patent claims.
    Technology
    Since 2017, Laxxon has held the exclusive worldwide license from Exentis Group AG and Exentis Knowledge GmbH for pharmaceutical applications of the technology behind SPID®.
    CEO and Chairman
    Helmut Kerschbaumer